Mount Sinai Health System will adopt its SOPHiA GENETICS’ AI-powered SOPHiA DDM Platform to enhance genomic testing and accelerate cancer research. Mount Sinai’s molecular pathology team will use the platform to strengthen next-generation sequencing capabilities for both blood cancers and solid tumors. The system is designed to identify complex genomic variants while streamlining analysis workflows and reducing manual interpretation time.

By integrating AI-driven analytics into its operations, Mount Sinai aims to improve efficiency in processing large genomic datasets and optimize laboratory resources, enabling clinicians to focus more on patient care.

“The collaboration between Mount Sinai and SOPHiA GENETICS reinforces our commitment to scientific innovation by integrating powerful digital tools into our workflows to support high-quality, data-driven cancer care. Leveraging SOPHiA DDM™ has enabled us to reduce hands-on analysis time and improve our test turnaround times, enabling our clinicians to provide better patient care,” said Jane Houldsworth, Director of Molecular Oncology Pathology at Mount Sinai.